In this month's "Hot Topic," Kevin Halling, M.D., Ph.D., discusses new next generation sequencing testing for various tumor types and the rationale for the enhancements that were made; reviews gene additions that are now available in each of the panels; and briefly speaks about the work that was done to validate cytology specimens for use in the subpanels.

In this month's "Hot Topic," David Viswanatha, M.D., discusses updates to Mayo Clinic's next-generation sequencing (NGS) for myeloid neoplasm evaluation, involving new test targets, the rationale for new genetic regions, alignments with the World Health Organization (WHO) guidelines and germline predisposition targets.

In this month's "Hot Topic," Anja Roden, M.D., discusses the role of PD-L1 interaction in the immune system, challenges of PD-L1 testing, and current PD-L1 companion testing in various tumor types.

In this month's "Hot Topic," Rajiv Pruthi, M.B.B.S., discusses heparin induced thrombocytopenia (HIT), approach diagnosis, and the role of the functional serotonin release assay (SRA).

In this month's "Hot Topic," Robin Patel, M.D., discusses how the use of multiplex tests may reduce the turnaround time for identifying the cause of bloodstream infections, and how this might impact antibiotic stewardship and patient outcomes.

In this month's "Hot Topic," Matthew Binnicker, Ph.D., discusses the use of multiplex panels for the diagnosis of respiratory infections and focuses on the clinical utility of these tests in the setting of upper respiratory tract infections.

In this month's "Hot Topic," Elitza Theel, Ph.D., will be discussing laboratory utilization management, specifically for diagnostic testing for tick-borne diseases.

In this month's "Hot Topic," Alicia Algeciras, Ph.D., DABCC, and Joshua Bornhorst, Ph.D., DABCC, discuss Alzheimer's disease CSF biomarkers.

In this month’s “Hot Topic,” Elitza Theel, Ph.D., discusses the modified two-tiered testing algorithm for Lyme disease entirely based on enzyme immunoassays (EIA).

In this month’s “Hot Topic,” Julia Lehman, M.D., discusses a recent change to the direct immunofluorescence assay, specifically the addition of the IgG4 conjugate.

This is a 6-part series describing the products and clinical tools of a laboratory quality improvement project called Region 4 Stork, or R4S.

In this month’s “Hot Topic,” Andrew McKeon, M.B., B.Ch., M.D., reviews the use of neurological phenotype-based evaluations, the move away from the paraneoplastic evaluation, and upcoming changes to test profiles.